Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

May 27, 2019Open Access

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

CMCristina MüllerPaul Scherrer Institute CUChristoph A. UmbrichtPaul Scherrer Institute NGNadezda GrachevaPaul Scherrer Institute

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

161Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of 161Tb-PSMA-617 for the treatment of mCRPC.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Müller et al. (Mon,) studied this question.

synapsesocial.com/papers/69dab71478a3e0e288684188 https://doi.org/https://doi.org/10.1007/s00259-019-04345-0

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy2018 · 147 citations
2Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.2006 · 82 citations
3Antitumor Effects and Normal-Tissue Toxicity of <sup>111</sup>In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing <i>HER</i>-Positive Human Breast Cancer Xenografts2010 · 76 citations
4Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.2006 · 107 citations
5<sup>225</sup>Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer2016 · 1,102 citations